Cargando…
Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists
BACKGROUND AND AIMS: The recognition of transarterial chemoembolization (TACE) failure/refractoriness among Chinese clinicians remains unclear. Using an online survey conducted by the Chinese College of Interventionalists (CCI), the aim of this study was to explore the recognition of TACE failure/re...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369015/ https://www.ncbi.nlm.nih.gov/pubmed/34447681 http://dx.doi.org/10.14218/JCTH.2021.00049 |
_version_ | 1783739201772060672 |
---|---|
author | Zhong, Bin-Yan Wang, Wan-Sheng Zhang, Shen Zhu, Hai-Dong Zhang, Lei Shen, Jian Zhu, Xiao-Li Teng, Gao-Jun Ni, Cai-Fang |
author_facet | Zhong, Bin-Yan Wang, Wan-Sheng Zhang, Shen Zhu, Hai-Dong Zhang, Lei Shen, Jian Zhu, Xiao-Li Teng, Gao-Jun Ni, Cai-Fang |
author_sort | Zhong, Bin-Yan |
collection | PubMed |
description | BACKGROUND AND AIMS: The recognition of transarterial chemoembolization (TACE) failure/refractoriness among Chinese clinicians remains unclear. Using an online survey conducted by the Chinese College of Interventionalists (CCI), the aim of this study was to explore the recognition of TACE failure/refractoriness and review TACE application for hepatocellular carcinoma (HCC) treatment in clinical practice. METHODS: From 27 August 2020 to 30 August 2020 during the CCI 2020 annual meeting, a survey with 34 questions was sent by email to 264 CCI clinicians in China with more than 10 years of experience using TACE for HCC treatment. RESULTS: A total of 257 clinicians participated and responded to the survey. Most participants agreed that the concept of “TACE failure/refractoriness” has scientific and clinical significance (n=191, 74.3%). Nearly half of these participants chose TACE-based combination treatment as subsequent therapy after so-called TACE failure/refractoriness (n=88, 46.1%). None of the existing TACE failure/refractoriness definitions were widely accepted by the participants; thus, it is necessary to re-define this concept for the treatment of HCC in China (n=235, 91.4%). Most participants agreed that continuing TACE should be performed for patients with preserved liver function, presenting portal vein tumor thrombosis (n=242, 94.2%) or extrahepatic spread (n=253, 98.4%), after the previous TACE treatment to control intrahepatic lesion(s). CONCLUSIONS: There is an obvious difference in the recognition of TACE failure/refractoriness among Chinese clinicians based on existing definitions. Further work should be carried out to re-define TACE failure/refractoriness. |
format | Online Article Text |
id | pubmed-8369015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | XIA & HE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83690152021-08-25 Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists Zhong, Bin-Yan Wang, Wan-Sheng Zhang, Shen Zhu, Hai-Dong Zhang, Lei Shen, Jian Zhu, Xiao-Li Teng, Gao-Jun Ni, Cai-Fang J Clin Transl Hepatol Original Article BACKGROUND AND AIMS: The recognition of transarterial chemoembolization (TACE) failure/refractoriness among Chinese clinicians remains unclear. Using an online survey conducted by the Chinese College of Interventionalists (CCI), the aim of this study was to explore the recognition of TACE failure/refractoriness and review TACE application for hepatocellular carcinoma (HCC) treatment in clinical practice. METHODS: From 27 August 2020 to 30 August 2020 during the CCI 2020 annual meeting, a survey with 34 questions was sent by email to 264 CCI clinicians in China with more than 10 years of experience using TACE for HCC treatment. RESULTS: A total of 257 clinicians participated and responded to the survey. Most participants agreed that the concept of “TACE failure/refractoriness” has scientific and clinical significance (n=191, 74.3%). Nearly half of these participants chose TACE-based combination treatment as subsequent therapy after so-called TACE failure/refractoriness (n=88, 46.1%). None of the existing TACE failure/refractoriness definitions were widely accepted by the participants; thus, it is necessary to re-define this concept for the treatment of HCC in China (n=235, 91.4%). Most participants agreed that continuing TACE should be performed for patients with preserved liver function, presenting portal vein tumor thrombosis (n=242, 94.2%) or extrahepatic spread (n=253, 98.4%), after the previous TACE treatment to control intrahepatic lesion(s). CONCLUSIONS: There is an obvious difference in the recognition of TACE failure/refractoriness among Chinese clinicians based on existing definitions. Further work should be carried out to re-define TACE failure/refractoriness. XIA & HE Publishing Inc. 2021-08-28 2021-04-08 /pmc/articles/PMC8369015/ /pubmed/34447681 http://dx.doi.org/10.14218/JCTH.2021.00049 Text en © 2021 Authors. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Zhong, Bin-Yan Wang, Wan-Sheng Zhang, Shen Zhu, Hai-Dong Zhang, Lei Shen, Jian Zhu, Xiao-Li Teng, Gao-Jun Ni, Cai-Fang Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists |
title | Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists |
title_full | Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists |
title_fullStr | Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists |
title_full_unstemmed | Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists |
title_short | Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists |
title_sort | re-evaluating transarterial chemoembolization failure/refractoriness: a survey by chinese college of interventionalists |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369015/ https://www.ncbi.nlm.nih.gov/pubmed/34447681 http://dx.doi.org/10.14218/JCTH.2021.00049 |
work_keys_str_mv | AT zhongbinyan reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists AT wangwansheng reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists AT zhangshen reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists AT zhuhaidong reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists AT zhanglei reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists AT shenjian reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists AT zhuxiaoli reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists AT tenggaojun reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists AT nicaifang reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists |